TORONTO, Jan. 16, 2013 (GLOBE NEWSWIRE) -- GeneNews Limited (TSX:GEN) ("GeneNews" or the "Company") today announced an extension to the term of certain share purchase warrants (the "Warrants"), subject to the approval of a majority of disinterested shareholders at a special meeting (including any adjournments or postponements thereof, the "Meeting") to be held at the offices of Fasken Martineau DuMoulin LLP at 333 Bay Street, Suite 2400, Bay Adelaide Centre, Toronto, ON M5H 2T6, Canada on Friday, February 22, 2013, at 10:00 a.m. (Eastern time). The expiry date of the Warrants would be extended as follows:
- 2,978,065 Warrants amended and restated on January 16, 2012, exercisable into 521,161 Common Shares, having an exercise price of $1.44 per Common Share and expiring February 1, 2013 (the "2012 Warrants") would be extended to February 1, 2015 effective January 31, 2013;
- 12,752,208 Warrants dated June 8, 2011, exercisable into 2,231,636 Common Shares, having an exercise price of $1.44 per Common Share and expiring February 1, 2013 (together with the 2012 Warrants, the "February Warrants") would be extended to February 1, 2015 effective January 31, 2013; and
- 4,250,903 Warrants dated November 12, 2010, exercisable into 743,908 Common Shares, having an exercise price of $1.44 per Common Share and expiring on June 1, 2013 (the "June Warrants") would be extended to June 1, 2015 effective the date of the Meeting.
Between February 1, 2013 and the date of the Meeting, no February Warrants may be exercised. If the requisite shareholder approval is not received, the February Warrants will terminate as at the date of the Meeting and the June Warrants will terminate on June 1, 2013.A bout GeneNews GeneNews is a molecular diagnostics company focused on the application of functional genomics to enable early diagnosis and personalized health management based on disease specific biomarkers. The Company has a patented core platform technology, the Sentinel Principle®, which has the power to detect and stage virtually any disease or medical condition from a simple blood sample. GeneNews is currently applying the Sentinel Principle® in major areas with unmet clinical needs such as cancer, arthritis, cardiovascular disease and neurological disorders. GeneNews' lead product, ColonSentry™, is the world's first blood test to pre-screen and assess an individual's current risk for colorectal cancer. For more information on GeneNews and ColonSentry™, go to www.GeneNews.com or www.ColonSentry.com. Forward-Looking Statements This press release contains forward-looking statements, which reflect GeneNews' current expectations regarding the future extension of the warrants of GeneNews. The forward-looking statements involve risks and uncertainties, including the result of the disinterested shareholder vote to extend the Warrants. Actual events could differ materially from those projected herein. Investors should consult the Company's ongoing quarterly filings, annual information form and annual reports for additional information on risks and uncertainties relating to these forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. Subject to applicable law, the Company disclaims any obligation to update these forward-looking statements.
CONTACT: Company Contact: Gailina Liew President & COO Office: (905) 739-2036 Mobile: (416) 844-0649 firstname.lastname@example.org Investor & Media Contact: Stephen Kilmer Kilmer Lucas Inc. Office: (212) 618-6347 Mobile: (905) 906-6908 email@example.com